Inhibition of PHLPP1 ameliorates cardiac dysfunction via activation of the PI3K/Akt/mTOR signalling pathway in diabetic cardiomyopathy.

Mingjun ZhangXuyang WangMing LiuDian LiuJinyu PanJingjing TianTao JinYunfan XuFengshuang An

Published in: Journal of cellular and molecular medicine (2020)

Our study indicated that PHLPP1 inhibition alleviated cardiac dysfunction via activating the PI3K/Akt/mTOR signalling pathway in DCM. Therefore, PHLPP1 may be a novel therapeutic target for human DCM.

Keyphrases

left ventricular
endothelial cells
oxidative stress
type diabetes
heart failure
signaling pathway
mouse model
atrial fibrillation
pluripotent stem cells